Quantcast

Latest Hepatitis C virus Stories

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...

2014-04-14 12:05:11

High cure rates achieved with fixed-dose interferon-free and ribavirin-free regimen Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver...

2014-04-09 15:57:54

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress™ (ILC). These EASL recommendations reflect the approval of three new direct-acting antivirals (DAAs) during 2014 by the European Medicines Agency. It is estimated that approximately 185 million people are infected with HCV on a global scale, with approximately 150 million people living with chronic...

2014-03-05 08:28:56

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 - LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study...

2014-02-20 12:10:40

Infection is a major global health problem affecting 160 million people worldwide Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 million Americans. Joseph Marcotrigiano, associate professor of chemistry and chemical biology, says this new research – published online today in Nature – describes an outer region of...

2013-12-04 23:02:58

Reportbuyer.com just published a new market research report: Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022. London (PRWEB) December 04, 2013 Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no...

Hepatitis C Vaccine Efforts Bring Vaccine Closer To Reality
2013-11-30 05:22:41

redOrbit Staff & Wire Reports - Your Universe Online A hepatitis C vaccine is one step closer thanks to the efforts of scientists at The Scripps Research Institute (TSRI), who have managed to discover unexpected structural features of a protein used by the virus to infect liver cells. The study authors, whose work appears in Friday’s edition of the journal Science, state any successful hepatitis C vaccine would most likely target this protein, which is known as E2 envelope...

2013-11-26 23:32:05

AllMed webinar provides in-depth review of the latest in the standard of care for the treatment of hepatitis C virus (HCV) infection. Portland, OR (PRWEB) November 26, 2013 As the treatment of HCV continues to evolve, new and increasingly complex protocols present additional challenges in providing optimal care while meeting the unique needs of individual patients with HCV. During a recent webinar hosted by AllMed Healthcare Management, Dr. Anca Pop, board-certified gastroenterologist and...


Latest Hepatitis C virus Reference Libraries

11_c18ff18c314281da28f1d18fa4357602
2011-01-20 19:28:48

Hepatitis E virus is an infective organism. The viral particles are 27 to 34 nanometers in diameter. They are non-enveloped and contain a single-strand of positive-sense RNA which is approximately 7300 bases in length. The virus was first visualized in 1983 and molecularly cloned in 1990. Previously it was classified in the family Caliciviridae. Its genome more closely resembles the rubella virus and is now classified as the only member of the genus Hepevirus which has not yet been...

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (2 articles) »
Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'